Compare Heron Therapeutics Inc (HRTX) vs PayPal Holdings, Inc. (PYPL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs PayPal Holdings, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.39 (market cap $68.01M), while PayPal Holdings, Inc. trades at $55.57 (market cap $47.07B). The key difference: PayPal Holdings, Inc. is far larger — about 692.1× Heron Therapeutics Inc's market cap, and PayPal Holdings, Inc. pays a 1.02% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and PayPal Holdings, Inc. for 106 Days on average.
| HRTX | PYPL | |
|---|---|---|
Market Cap | $68.01M | $47.07B |
Volume | 1,891,941 | 13,860,099 |
Sector | Health | Financials |
52-Week High | $1.49 | $75.75 |
52-Week Low | $0.27 | $39.08 |
Typical Hold Time | 35 Days | 106 Days |
Enterprise Value | $174.75M | $49.21B |
Dividend Yield | — | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
PayPal (PYPL) trades at $54.95, up 0.62% today, with a bullish technical signal from moving averages and a consensus analyst price target of $56.47. The stock shows strong profitability with a 14.36% net income margin and 24.5% ROE, while recent earnings beats in Q1 and Q2 2026 and a new Meta partnership for AI-powered checkout signal positive momentum. Cash flow remains robust with $1.53B net cash flow in 2025.
PYPL presents a value opportunity with a low P/E of 10.4, but faces risks from competitive pressures in digital payments and slowing branded checkout growth. Wall Street sentiment is mixed with 35.71% buy ratings, yet the stock's current discount to historical highs and cost-cutting initiatives under new CEO Enrique Lores offer potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →
